Drug intelligence / Profile preview

FortiVac-Dengue

Development stage: Preclinical
Lead developer: Multimeric Biotherapeutics
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

FortiVac-Dengue is a recombinant fusion protein vaccine candidate developed by Multimeric Biotherapeutics for the prevention of dengue fever. It utilizes the company's proprietary SPD-Antigen-CD40L platform, which incorporates a surfactant protein D (SPD) multimerization domain, dengue-specific antigens, and a CD40 ligand (CD40L) domain. This construct is designed to specifically target and activate CD40 on dendritic cells, thereby enhancing antigen cross-presentation and stimulating potent CD8+ T-cell mediated immunity. The program is currently in the IND-enabling preclinical stage of development.

Targets

CD40 (Cluster of differentiation 40 receptor)

Beyond the preview

Go deeper on FortiVac-Dengue.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FortiVac-Dengue.

Explore the full profile